



# ATTORNEY'S DOCKET NUMBER: 2003080-0071 (SK-744-CON4)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Danishefsky et al.

Examiner:

Solola, T. A.

Serial No.:

10/004,571

Art Unit:

1626

Filed:

December 4, 2001

For:

Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof

Mail Stop: Amendments Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

# TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Form PTO-1449 (21 page);
- 2. Supplemental Information Disclosure Statement (5 pages);
- 3. Transmittal Letter (1 page).
- 4. Cited Art (434); and
- 5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

C. Hunter Baker, M.D., Ph.D. Registration Number 46,533

Choate, Hall & Stewart Exchange Place 53 State Street Boston, MA 02109 (617) 248-5000 (617) 248-4000

Dated: 2/4/2005

3814598

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

Signature

Sandra Saccocia

Typed or Printed Name of person signing certificate

# FIRST TRADERING

# **ATTORNEY'S DOCKET NUMBER: 2003080-0071 (SK-744-CON4)**

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Danishefsky et al.

Examiner:

Solola, T. A.

Serial No.:

10/004,571

Art Unit:

1626

Filed:

December 4, 2001

For:

Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof

Mail Stop: Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## **INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

### Type of Statement

The present Information Disclosure Statement is:

- [ ] An original Information Disclosure Statement; or
- [X] A supplemental Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria,

VA 22313-1450.

Date

Signature

Sandra Saccocia

Name of Person Signing

# Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

[X]	Pursu	ant to 37	7 CFR § 1.97(b); no fee or certification is required:
	[]	Withi	n three months of the filing date of a national application other than
		a conf	tinued prosecution application under § 1.53(d);
	[]	Withi	n three months of the date of entry of the national stage as set forth
		in § 1	.491 in an international application;
	[X]	Befor	e the mailing of a first Office action on the merits; or
	[]	Befor	e the mailing of a first Office action after the filing of a request for
		contir	nued examination under § 1.114.
[]	Pursu	ant to 37	7 CFR § 1.97(c) after the dates listed above but before the mailing
	date o	of any of	a final action under § 1.113, a notice of allowance under § 1.311, or
	an act	ion that	otherwise closes prosecution in the application; Applicant hereby
	either	•	
	[]	Certif	ies that either:
		[]	each item of information contained in the information disclosure
			statement was first cited in any communication from a foreign
			patent office in a counterpart foreign application not more than
			three months prior to the filing of the information disclosure
			statement; or
		[]	That no item of information contained in the information
			disclosure statement was cited in a communication from a foreign
			patent office in a counterpart foreign application, and, to the
			knowledge of the person signing the certification after making
			reasonable inquiry, no item of information contained in the
			information disclosure statement was known to any individual

Page 2 of 5 3814577

the information disclosure statement; or [] Includes herewith the fee set forth in § 1.17(p), [] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby both: Certifies that either: [] [] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and

Includes herewith the fee set forth in  $\S 1.17(p)$ .

[]

designated in § 1.56(c) more than three months prior to the filing of

Page 3 of 5 3814577

#### Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [X] A copy of each cited reference not indicated with an asterisk is included;
- [ ] Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

[ ] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement either:

- [ ] Does not contain non-English language citations;
- [ ] Includes one or more translations of a non-English citation; or
- [X] Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a

representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an

admission that the information cited in the statement is, or is considered to be, material to patentability as

defined in  $\S 1.56(b)$ .

The submission of this Information Disclosure Statement shall not be construed as a

representation that the information cited in the Statement is, or is considered to be, in fact, prior art as

defined by 35 USC §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other

information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited

patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during

the examination of this application; and

The citations for the patent(s) and publication(s) be printed on any patent which issues 3.

from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own

conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: 2/9/2005

C. Hunter Baker, M.D., Ph.D.

Registration Number: 46,533

CHOATE, HALL & STEWART

**Exchange Place** 53 State Street

Boston, Massachusetts 02109

(617) 248-5000

(617) 248-4000

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Talent and Trademark Office			ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLIC NO.:10/	
INFORMATIO	ADISCIO SURE	STATEMENT	APPLICANT: Danishef	sky et al.	
(Use several sheets if necessary)			FILING DATE:	GROUP	):
			December 4, 2001	1626	
U.S. PATENT I	DOCUMENTS				
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	6,090,601	Gustafsson	July 18, 2000	435	183
* OFFI	6,096,757	Bishop	August 1, 2000	514	290
	6,117,659	Ashley	September 12, 2000	435	155
1 1 j, 18 1, j	6,121,029	Schupp	September 19, 2000	435	183
	6,211,412	Georg	April 3, 2001	568	309
	6,221,641	Khosla	April 24, 2001	435	193
	6,251,636	Betlach	June 26, 2001	435	76
	6,262,107	Li	July 17, 2001	514	449
	6,280,999	Gustafsson	August 28, 2001	435	252.3
	6,407,103	Nugiel et al.	June 18, 2002	514	232.8
	6,419,692	Yang et al.	July 16, 2002	623	115
4	6,441,186	Nicolaou et al.	August 27, 2002	548	204
	6,457,303	Georg et al.	October 1, 2002	56	465
	6,489,314	Ashley et al.	December 3, 2002	514	183
	6,498,257	Vite et al.	December 24, 2002	548	205
	6,576,651	Bandyopadhyay et al.	June 10, 2003	514	365
	6,596,875	White et al.	July 22, 2003	548	204
	6,670,384	Bandyopadhyay et al.	December 30, 2003	514	365
	6,683,100	Van Hoogevest	January 27, 2004	514	365
	6,686,380	Lee	February 3, 2004	514	365
1 P P 2	6,689,802	DiMarco et al.	February 10, 2004	514	365
	6,719,540	Regueiro-Ren et al.	April 13, 2004	417	365
	6,723,854	Danishefsky et al.	April 20, 2004	548	203
	6,727,276	Lee	April 27, 2004	514	540
	6,730,699	Li et al.	May 4, 2004	514	449
	6,730,803	Iwasaki et al.	May 4, 2004	558	442
	6,780,620	Li et al.	August 24, 2004	435	117

FORM PTO-1 (REV. 8-83)	Comn	Department of nerce t and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLIC NO.:10/0	
INFORMATION DISCLOSURE STATEMENT			(5)(-747-6014)		
			APPLICANT: Danishef		
(Use several sheets if necessary)  U.S. PATENT APPLICATIONS			FILING DATE: December 4, 2001	GROUP: 1626	
			December 4, 2001	1020	
		T			
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
	2002/0086812	Schweinfest et al.	July 4, 2002		
	2002/0115686	Hoogevest	August 22, 2002		
	2002/0119202	Hunter et al.	August 29, 2002		
	2002/0137152	Santi et al.	September 26, 2002		
	2002/0143038	Bandyopadhyay et al.	October 3, 2002		
	2002/0147197	Newman et al.	October 10, 2002		
	2002/0156110	Arslanian et al.	October 24, 2002		
	2002/0156289	Georg et al.	October 24, 2002		
	2002/0164377	Hunter et al.	November 7, 2002		
	2002/0165258	Lee	November 7, 2002		
	2002/0165257	Lee	November 7, 2002		
	2002/0165265	Hunter et al.	November 7, 2002		
	2002/0165415	Georg et al.	November 7, 2002		
	2002/0169125	Leung et al.	November 14, 2002		
	2002/0169135	Pardee et al.	November 14, 2002		
	2002/0169190	Bandyopadhyay et al.	November 14, 2002		
	2002/0177615	Bandyopadhyay et al.	November 28. 2002		
	2002/0192778	Schupp et al.	December 19, 2002		
	2002/0193361	Ashley et al.	December 19, 2002		
	2002/0197261	Li et al.	December 26, 2002		
	2002/0198141	McChesney et al.	December 26, 2002		
	2003/0191089	Regueiro-Ren et al.	October 9, 2003		
	2003/0187273	White et al.	October 2, 2003		
	2003/0139460	Schwede et al.	July 24, 2003		
	2003/0134883	Myles et al.	July 17, 2003		
	2003/0130178	Li et al.	July 10, 2003		
	2003/0130170	Li et al.	July 10, 2003		

Comme		Department of merce	ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
		t and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT			APPLICANT: Danisher	fsky <i>et al</i> .
(Use sever	(Use several sheets if necessary)			GROUP:
				1626
	2003/0124055	Li et al.	July 3, 2003	
	2003/0125362	Danishefsky et al.	July 3, 2003	
	2003/0113335	Li et al.	June 19, 2003	
	2003/0114363	Li et al.	July 3, 2003	
	2003/0114450	Santi et al.	June 19, 2003	
	2003/0114504	Webster et al.	June 19, 2003	
	2003/0114518	Li et al.	June 19, 2003	
	2003/0105330	Danishefsky et al.	June 5, 2003	
	2003/0109500	Pero et al.	June 12, 2003	
	2003/0096381	Julien et al.	May 22, 2003	
	2003/0073677	Lee	April 17, 2003	
	2003/0073617	Li et al.	April 17, 2003	
	2003/0073615	Li et al.	April 17, 2003	
,	2003/0073205	Arslanian et al.	April 17, 2003	
	2003/0060623	Vite et al.	March 27, 2003	
	2003/0054977	Kumar et al.	March 20, 2003	
	2003/0049841	Short et al.	March 13, 2003	
	2003/0045711	Ashley et al.	March 6, 2003	
	2003/0036515	Pardee et al.	February 20, 2003	
	2003/0036177	Strohhacker	February 20, 2003	
	2003/0004338	Li et al.	January 2, 2003	
	2003/0004209	Hunter et al.	January 2, 2003	
	2003/0003094	Hunter et al.	January 2, 2003	
	2004/0023345	Vite et al.	February 5, 2004	
	2004/0024032	Voi et al.	February 5, 2004	
	2004/0024033	O'Reilly et al.	February 5, 2004	
	2004/0030147	White et al.	February 12, 2004	
	2004/0038324	Atadja et al.	February 26, 2004	
	2004/0039026	Nicolaou et al.	February 26, 2004	
	2004/0044203	Wittman et al.	March 4, 2004	

Commo		Commerce		IN RE APPLICATION
(REV. 8-83)	Paten	t and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATI	ON DISCLOSURE	STATEMENT	APPLICANT: Danished	fsky et al.
(Use several sheets if necessary)			FILING DATE:	GROUP:
			December 4, 2001	1626
	2004/0044221	Danishefsky et al.	March 4, 2004	
	2004/0049051	Hoefle et al.	March 11, 2004	
	2004/0053910	Danishefsky et al.	March 18, 2004	
	2004/0053978	Lee et al.	March 18, 2004	
	2004/0053995	Danishefsky et al.	March 18, 2004	
	2004/0054186	Das et al.	March 18, 2004	
	2004/0087610	Pardee et al.	May 6, 2004	
	2004/0087634	Hoefle et al.	May 6, 2004	
	2004/0092478	Rothermel et al.	May 13, 2004	
	2004/0092514	Velaparthi et al.	May 13, 2004	
	2004/0092560	Hoefle et al.	May 13, 2004	
	2004/0097517	Dwyer et al.	May 20, 2004	
,	2004/0102451	Guzi et al.	May 27, 2004	
	2004/0102452	Guzi et al.	May 27, 2004	
	2004/0102495	Danishefsky et al.	May 27, 2004	
	2004/0106624	Guzi et al.	June 3, 2004	
s - s - 11 <del>111</del>	2004/0106985	Jang	June 3, 2004	
	2004/0116442	Guzi et al.	June 17, 2004	
	2004/0126379	Adolf et al.	July 1, 2004	
	2004/0127432	Nicolaou et al.	July 1, 2004	
	2004/0132146	Benigni et al.	July 8, 2004	
	2004/0133271	Jang	July 8, 2004	
	2004/0132692	Sherrill et al.	July 8, 2004	
	2004/0132736	Guzi et al.	July 8, 2004	
	2004/0132754	Brandt et al.	July 8, 2004	
	2004/0142931	Vite et al.	July 22, 2004	
	2004/0142990	Hofmann et al.	July 22, 2004	
	2004/0152708	Li et al.	August 5, 2004	
FOREIGN PA	TENT DOCUMEN	<u>.i.</u>	<u> </u>	
Examiner's	Document No.	Country	Date	Translation

Comme		Department of nerce t and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)		CATION /004,571
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANT: Danishefsky et al.		
			FILING DATE:	GROU	P:
(Use several sneets if necessary)			December 4, 2001	1626	
Initials				Yes	No
	DE 41 38 042	Germany	19 November 1991		
	DE 196 07 702	Germany	29 February 1996		
	DE 196 38 870	Germany	23 September 1996		
	DE 197 01 758	Germany	20 January 1997		
	DE 197 13 970	Germany	04 April 1997		
	DE 197 20 312	Germany	15 May 1997		
	DE 197 26 627	Germany	17 June 1997		
	DE 197 35 574	Germany	09 August 1997		
	DE 197 35 575	Germany	09 August 1997		
	DE 197 35 578	Germany	09 August 1997		
	DE 197 44 135	Germany	29 September 1997		
	DE 197 49 717	Germany	31 October 1997		
	DE 197 51 200	Germany	13 November 1997		
	DE 198 13 821	Germany	20 March 1998		
	DE 198 21 954	Germany	15 May 1998		
	DE 198 33 750	Germany	16 July 1998		
	DE 198 46 493	Germany	09 October 1998		
	DE 198 30 060	Germany	30 June 1998		
	DE 198 49 464	Germany	21 October 1998		
	DE 199 08 763	Germany	18 February 1999		
	DE 199 08 765	Germany	18 February 1999		
	DE 199 08 767	Germany	19 October 2000		
	DE 199 23 001	Germany	13 May 1999		
	DE 199 30 111	Germany	01 July 1999		
	DE 199 54 228	Germany	04 November 1999		
	DE 199 54 230	Germany	04 November 1999		
	DE 100 51 136	Germany	16 October 2000		
	DE 100 15 836	Germany	27 March 2000		

Comm			ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
		and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANT: Danishef	sky et al.
			FILING DATE:	GROUP:
				1626
	DE 100 20 517	Germany	19 April 2000	
	DE 100 20 899	Germany	20 April 2000	
	EP 1 440 973	Europe	July 28, 2004	
	EP 1 428 826	Europe	June 16, 2004	
	EP 1 407 784	Europe	April 14, 2004	
	EP 1 386 922	Europe	February 4, 2004	
	EP 1 340 498	Europe	September 3, 2003	
	EP 1 275 648	Europe	15 January 2003	
	EP 1 201 666	Europe	02 May 2002	
	EP 1 186 606	Europe	17 March 2002	
	EP 1 121 364	Europe	13 March 2002	
	EP 1 001 951	Europe	25 September 2002	
	EP 0 975 638	Europe	07 August 2002	
	EP 0 975 622	Europe	09 October 2002	
	WO 04/080458	International	September 23, 2004	
	WO 04/063151	International	July 29, 2004	
	WO 04/061116	International	July 22, 2004	
	WO 04/056832	International	July 8, 2004	
	WO 04/054622	International	July 1, 2004	
	WO 04/054514	International	July 1, 2004	
	WO 04/052401	International	June 24, 2004	
	WO 04/030620	International	April 15, 2004	
	WO 04/028610	International	April 8, 2004	
	WO 04/028582	International	April 8, 2004	
	WO 04/025254	International	April 1, 2004	
	WO 04/026877	International	April 1, 2004	
	WO 04/026872	International	April 1, 2004	
	WO 04/026867	International	April 1, 2004	
	WO 04/026310	International	April 1, 2004	
	WO 04/026229	International	April 1, 2004	

FORM PTO-1449 (REV. 8-83)	Comm	Department of nerce and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION I	DISCLOSURE S	STATEMENT	APPLICANT: Danishefsky et al.	
(Use several	sheets if necessa	ıry)	FILING DATE:	GROUP:
	(Use several sheets if necessary)			1626
V	VO 04/024735	International	March 25, 2004	
V	VO 04/022560	International	March 18, 2004	
V	VO 04/022080	International	March 18, 2004	
V	VO 04/022062	International	March 18, 2004	
V	VO 04/018635	International	March 4, 2004	
v	VO 04/016269	International	February 26, 2004	
v	VO 04/012735	International	February 12, 2004	
V	VO 03/084536	International	October 16, 2003	
V	VO 03/078411	International	September 25, 2003	
V	VO 03/077903	International	September 25, 2003	
V	VO 03/075899	International	September 18, 2003	
·	VO 03/074521	International	September 12, 2003	
V	VO 03/074053	International	September 12 2003	
V	VO 03/070170	International	13 February 2002	
V	VO 03/018002	International	06 March 2003	
V	VO 03/014068	International	20 February 2003	
V	VO 03/014063	International	20 February 2003	
V	VO 03/007924	International	30 January 2003	
V	VO 02/098868	International	14 May 2002	
V	VO 02/096281	International	December 5, 2004	
V	VO 02/072085	International	19 September 2002	
V	VO 02/067941	International	06 September 2002	
V	VO 02/046196	International	13 June 2002	
V	VO 02/030356	International	April 18, 2002	
W	VO 01/010412	International	02 August 2000	
V	VO 01/007439	International	24 July 2000	
W	VO 00/071521	International	15 May 2000	
W	VO 00/066589	International	01 May 2000	
V	VO 00/058254	International	23 March 2000	
V	VO 00/057874	International	20 March 2000	

Comme		Commerce		IN RE APPLICATION
		and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANT: Danishef	sky et al.
			FILING DATE:	GROUP:
			December 4, 2001	1626
	WO 00/049020	International	18 February 2000	
	WO 00/049019	International	18 February 2000	
	WO 00/047584	International	11 February 2000	
	WO 00/039276	International	21 December 1999	
	WO 00/037473	International	20 December 1999	
	WO 00/031247	International	19 November 1999	
	WO 00/000485	International	30 June 1999	
	WO 99/067253	International	21 June 1999	
	WO 99/066028	International	16 June 1999	
	WO 99/065913	International	18 June 1999	
	WO 99/059985	International	25 November 1999	
	WO 99/058534	International	07 May 1999	
	WO 99/054319	International	05 April 1999	
	WO 99/054318	International	05 April 1999	
	1			
Examiner's Initials	Citation (Includin	g Author, Title, Date, Pe	rtinent Pages, Etc.)	1940
		ural Analogues: The Pow	otubule Stabilizing Antitur ver of Sharpless' Asymmed	
	Cancer" Chimia,	54:612-621, 2000.	alogs-Potential New Weap	
			Evaluation of Highly Poter Lett. 10(24):2765-2768, 2	
	Altmann et al., "E	pothilones and Related S	Structures-A New Class of	Microtubule Inhibitors
	with Potent in vivo Antitumor Activity" <i>Biochim. Biophys. Acta</i> , <b>1470</b> (3):M79-M91, 2000.  Altmann <i>et al.</i> , "Synthetic and Semisynthetic Analogs of Epothilones: Chemistry and Biological Activity" <i>Book of Abstracts</i> , 219 <sup>th</sup> ACS National Meeting, San Francisco, CA, March 26-30, ORGN-287, 1999.			
	Altmann et al., "N Drugs" Curr. Opin	Aicrotubule-Stabilizing And Chem. Biol., 5(4):424-		
	11(9):678-696, 19	98.	ilones: Highlights from a \	·
	Arsianian et al.,	A New Cyloloxic Epolini	lone from Modified Polyko	ende Synniases

FORM PTO-1449	U.S. Department of Commerce	ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION D	ISCLOSURE STATEMENT	APPLICANT: Danishefsky	y et al.
(Use several s	sheets if necessary)	FILING DATE:	GROUP:
		December 4, 2001	1626
Не	eterologously Expresssed in Myxococcus	xanthus" J. Nat. Prod. 65:10	061-1064, 2002.
19	vila et al., "The Use of Microtubule Pois 97.		
M	wada et al., "New Cytotoxic Agents and etastatic" Breast Cancer Review 4-15, 20	002.	
	aggiolini <i>et al.</i> , "Stereocontrolled Total S a, 25-Dihydroxyergocalciferol" J. Org. C		ycholecalciferol and
Ba Ch	nik et al., "Diastereoselective Cobalt-Cat nem. Soc. 123:5112-5113, 2001.	alyzed Aldol and Michael Cy	
Im	alog et al., "A Novel Aldol Condensation aproved Total Synthesis of Epothilone B"	'Angew. Chem. Int. Ed. 37(1	9):2675-2678, 1998.
Ba	log et al., "Total Synthesis of Epothilon	e A" Angew. Chem. Int. Ed. 6	51:2801-2803, 1996.
Ac 10	ellemin-Laponnaz <i>et al.</i> , "The Kinetic Recylation Catalyst: Application to Natural 10, 2000.	Product Synthesis" Chem. C	Commun. 12:1009-
the	ertinato et al., "Studies Toward a Synthes e Acyl Region and Models for Macrocyc eyer et al., "Metabolic Diversity in Myxo	lization" J. Org. Chem. 61:80	000-8001, 1996.
19	99.		
Ep	swas et al., "Highly Concise Routes to Eothilone 490" J. Am. Chem. Soc. 124:98	25-9832, 2002.	
Ide Ch	um et al., "In vivo Metabolism of Epothic entification of Three New Epothilone B laromatography/Mass Spectrometry/Tand ectrom. 15(1):41-49, 2001.	Metabolites by Capillary Higl	h-Pressure Liquid
Bo Su Dr	occi et al., "Protracted Low-Dose Effects rvival in Vitro Reveal a Selective Antiar ugs" Cancer Research 62:6938-6943, 20	ngiogenic Window for Variou 002.	s Chemotherapeutic
Th 20	oddy <i>et al.</i> , "Epothilone C. Macrolactonizationic idesterase Domain of Epothilone Polyke 02.	tide Synthase" J. Am. Chem.	Soc. 125:3428-3429,
Cy	ode et al., "Stereoselective Syntheses of I reloaddition" J. Am. Chem. Soc. 123(15)	3611-3612, 2001.	
	ode et al., "Stereoselective Syntheses of local or of local of loc	•	
Ke	ornscheuer et al., "Directed Evolution of by Intermediate in the Synthesis of Epoth	ilones" Biotechnol. Bioeng. 5	<b>8</b> (5):554-559, 1998.
•	orzilleri et al., "A Novel Application of a action to the Regio and Stereoselective S		

FORM PTO-1449	U.S. Department of Commerce	ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION DIS	SCLOSURE STATEMENT	APPLICANT: Danishefsky	et al.
(Use several sh	eets if necessary)	FILING DATE:	GROUP:
	·	December 4, 2001	1626
	ural Products" J. Am. Chem. Soc. 122(3		
the Cell Brui	ker et al., "Late Activation of Apoptoti Cytotoxic Effects of Discodermolide at s" Cancer Research 62(14):4081-4088 mmond et al., "A Novel Application of ction to the Regio- and Stereoselective	nd Epothilone B in Non-Smal , 2002. Ta Pd(0)-Catalyzed Nucleoph	l Cell Lung Cancer ilic Substitution
	ural Products" <i>Chemtracts</i> 14(7):401-4	•	ies of the Epotinione
Carl Rub Anti	omagno et al., "The High-Resolution Sulin: An Understanding of the Structur itumor Agents" Angew. Chem. Int. Ed.	Solution Structure of Epothilo e-Activity Relationships for a 42:2511-2515, 2003.	a Powerful Class of
Corr Epo	omagno et al., "Derivation of Dihedral related Relaxation Rates: A C-C Torsi thilone A Bound to Tubulin" Angew. C	on Involving a Quaternary Ca Chem. Int. Ed. <b>42</b> :2515-2517,	arbon Atom in 2003.
Mol	reira, "Discovery and Study of New Reecule Assembly" <i>Chimia</i> <b>55</b> (10):818-8	20, 2001.	
	as <i>et al.</i> , "BINOLAM, a Recoverable Calysis: The Asymmetric Synthesis of Co.		
Mol Abs	kravarty et al., "Taxoid and Non-Taxo ecular Modeling Approach to Eludicat tracts, 214th ACS National Meeting, L crican Chemical Society.	ion of a Common Pharmacop	hore" Book of
Cha Desc	ppell et al., "En Route to a Plant Scale oxyepothilone B" Org. Letter. 2(11):16	Synthesis of the Promising A 533-1636, 2000.	ntitumor Agent 12,13-
Che	n et al., "Epothilone Biosynthesis: Ass he EpoB Subunit" Chem. Biol. 8(9):899	sembly of the Methylthiazoly	lcarboxy Starter Unit
Mul	u <i>et al.</i> , "Quantitative Analysis of Dose tiple Drugs or Enzyme Inhibitors" <i>Adv</i>	. Enzyme Reg. 22:27-55, 1984	<u> </u>
pacl	u, "Desoxyepothilone B is curative aga itaxel" <i>Proc. Natl. Acad. Sci. USA</i> <b>95</b> :1	5798-15802, 1998.	
Mic Hun	u et al., "The Synthesis, Discovery, and rotubule Stabilization Agents: Curative nan Tumor Xenografts in Nude Mice".	e Effects of Desoxyepothilon Proc. Natl. Acad. Sci. USA 98	es B and F Against 3(14):8113-8118, 2001
with <b>95</b> :9	u et al., "Desoxyepothilone B: An Effi a Promising In Vivo Profile Relative to 642-9647, 1998.	to Epothione B" Proc. Natl. A	cad. Sci. USA
	u et al., "Desoxyepothilone B: An efficient and in vivo profile relative to epothics."  3.		_

FORM PTO-144	U.S. Department of	ATTY. DOCKET:	IN RE
	Commerce	2003080-0071	APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
		(SIZ / 11 GGIVI)	
INFORMATION	N DISCLOSURE STATEMENT	APPLICANT: Danishefsk	y et al.
(Use sever	ral sheets if necessary)	FILING DATE:	GROUP:
		December 4, 2001	1626
	Chou et al., "Design and Total Synthesis of which Eliminate Xenograft Tumors to a No. 42:4762-4767, 2003.	onrelapsable State" Angew. (	Chem. Int. Ed. Engl.
	Corey et al., "Chemistry of Diimide. Some Bonds" Tet. Lett. 11:347-352, 1961.		
	Correia et al., "Physiochemical Aspects of Pharm. Des. 7(13):1213-1228, 2001.		
	Cowden et al., "Cancer Drugs-Better than"		
	De Brabander et al., "Towards a Synthesis and C(7)-C(12) Fragments" Synlett. 7:824-	826, 1997.	
	Delbaldo <i>et al.</i> , "Nouveaux medicamenets <b>31</b> :802-809, 2002.	dans le cancer bronchique" l	La Presse Medicate
	Denmark et al., "Cyclopropanation with Denmark et al., "C		line) Palladium(II)
		lol Reaction of Tert-Butyl Acetate Using Titanium-	
	Ermolenko <i>et al.</i> , "Synthesis of Epothilone 2898, 2002.	s B and D from D-Glucose"	Tet. Lett. 43:2895-
	Essayan <i>et al.</i> , "Successful Parenteral Dese 97:42-46, 1996.		
	Fletcher et al., "Structure of the Mitogen-In TIS10-Encoded Protein Is a Functional Pro 4344, 1992.		
	Florsheimer et al., "Epothilones and Their Inhibitors" Expert Opin. Ther. Pat., 11(6):9	951-968, 2001.	_
	Frykman et al., "Control of Secondary Met the Dissolved Oxygen Tension" Biotechno.	l. Prog. 18:913-920, 2002.	
	Fürstner, "Olefin Metathesis and Beyond"	Angew. Chem. Int. Ed. Engl.	<b>39</b> :3013-3043, 2000.
	Furstner et al., "Concise Total Syntheses of Chem. Commun. 12:1057-1059, 2001.	<u> </u>	
	Agents" Abstr. PapAm. Chem. Soc., 221st	esign and Synthesis of De Novo Macrocyclic Hybrids as Potential Anticancer PapAm. Chem. Soc., 221 <sup>st</sup> , MEDI-130, 2001.	
	Georg et al., "Studies Toward the Synthesi 219th ACS National Meeting, San Francisc	o, CA, March 26-30, MEDI-	<i>075</i> , 2000.
	Gerlach et al., "Synthesis of the C(7)-C(17 Closing Metathesis Reaction" Synlett. 10:1	) Segment of Epothilones by	
	Gerth. et al., "Studies on the Biosynthesis of Monooxygenase" J. Antibiot., 54(2):144-14	of Epothilones: the PKS and	Epothilone C/D
	Gerth et al., "Epothilons A and B: Antifung		ds from Sorangium

FORM PTO-144	9 U.S. Department of Commerce	ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION	N DISCLOSURE STATEMENT	APPLICANT: Danishefsky	et al.
(Use sever	ral sheets if necessary)	FILING DATE:	GROUP:
		December 4, 2001	1626
	cellulosum (Myxobacteria) Production, Phy <i>Antibiotics</i> :49-53, 1996.		
	Gerth et al., "Studies on the Biosynthesis of Carbon Skeleton" J. Antibiot. 53(12):1373-	1377, 2000.	
	Giannakakou, et al., "A Common Pharmac Basis for Drug Resistance Conferred by Tu Natl. Acad. Sci., 97(6): 2904-2909, 2000.	bulin Mutations in Human C	ancer Cells" <i>Proc</i> .
	Griffin, et al., "Molecular Determinants of 2L/TRAIL-induced Apoptosis of Human C 37-47, 2003.		
	Grubbs, et al., "Ring-Closing Metathesis an Chem. Res. 28:446-452, 1995.	nd Related Processes in Organ	nic Synthesis" Acc.
	Gupta, et al., Understanding Tubulin-Taxo to Yeast Tubulin <i>PNAS</i> , <b>100</b> : 5394-6397, 2	nding Tubulin-Taxol Interactions: Mutations That Impart Taxol Binding S, 100: 5394-6397, 2003.	
	Haar, et al., "Discodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol", <i>Biochemistry</i> , <b>35</b> : 243-250, 1996.		s Microtubules More
		es from Sorangium Cellulosum, Strains So ce90/B2 and acidation and SAR Studies" <i>J. Nat. Prod.</i> , <b>64</b> (7): 847-	
	Harris, et al., Complex Target-Oriented Syn History in the dEpoB Series J. Org. Chem.,		Process: A Case
	Harris, et al., New Chemical Synthesis of the 13-Desoxyepothilone B: Discovery of a Sur Diastereoselectivity of an Aldol Condensat	rprising Long-Range Effect of	n the
	Harris, et al., "Chemical Synthesis and Bio Stabilizing Agents with Enhanced Activity Tumors", <i>Chemistry for the 21<sup>st</sup> Century</i> , 8	Against Multidrug-Resistant	
	Hayward, et al. "Total Synthesis of Rapamy Macrocyclization Reaction", J. Am. Chem.		ediated Aldol
	He, et al "Novel Molecules that Interact w Similar to Taxol" <i>Drug Discovery Today</i> , 6		unctional Activity
	He, Yun et al., "Total Synthesis and Biolog Research Institute Order No.: DA9966202	·	
	Hofle, et al., "Epothilone A-D and Their The Agents" Pure Appl. Chem., 71:2019-2024,	1999.	
	Hofle, et al., "N-Oxidation of Epothilone A	-C and O-Acyl Rearrangeme	nt to C-19 and C-21

FORM PTO-1449	U.S. Department of Commerce	ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
(REV. 8-83) Patent and Trademark Office		(SK-744-CON4)	NO.:10/004,571
INFORMATION 1	DISCLOSURE STATEMENT	APPLICANT: Danishefsl	ky et al.
(Use several sheets if necessary)		FILING DATE: December 4, 2001	GROUP: 1626
Is	Substituted Epothilones" Angew. Chem. In	t. Ed., 38(13/14):1971-1974	, 1999.
	Holland, et al., "Design, Synthesis and Bio Abstracts, 215th ACS National Meeting, D		
	vin, "Some Recent Applications of Olefin Mol. Catal. A: Chem, 133(1-2): 1998	Metathesis in Organic Synt	hesis: A Review", J.
ı	ulien, et al., "Isolation and Characterization of Characterization	<u>-</u>	thetic Gene Cluster from
2	Kalesse, et al., "The Formal Total Synthesi 823, 1999.		
I	Koch, et al., Diastereoselective Titanium Epothilones <i>Organic Letters</i> , <b>2</b> (22): 3811-3	814, 2002.	<u>,                                      </u>
F	Lee, et al., "BMS-247550: A Novel Epoth Paclitaxel but Possessing Superior Antitum 2001.		
I	Lee, et al., "Synthesis of the C11-C21 and C13-C21 Fragments of Epothilones from D-glucose" <i>Bull. Korean Chem. Soc.</i> , <b>21</b> (12): 1177-1178, 2000.		thilones from D-
	Lee, et al., "Synthesis Toward Epothilone A C1-C10 and the Allylic Bromide of C11-C		
	Lee, et al., "Insights into Long-Range Struction Condensations: A Practical Total Synthesis 249-5259, 2001.		
Ţ	Lee, et al., "Total Synthesis and Antitumor Unexpected Solvolysis Problem at C15, Machem., 65: 6525-6533, 2000.	•	
	Levin, et al., "An Alternative Procedure for Amides", Synth. Commun. 12: 989, 1982.	the Aluminum-Mediated C	Conversion of Esters to
I I	i, et al., "Synthesis of a Novel Epothilone PapAm. Chem. Soc. 221st, MEDI-137, 200	01	
A C	Li, et al., "Process Development of the Sen Analogue" Abstracts of Papers, 222 <sup>nd</sup> ACS DRGN-238, 2001.	National Meeting, Chicago	, IL, August 26-30,
I	i, et al., "Antimitotic Agents" Annu. Rep.	Med. Chem., 34: 139-148, 1	1999.
A	cichtner et al., "Subcellular Distribution of acad. Sci. U.S.A., 98(20): 11743-11748, 20	001.	
I F n	Lin, et al., "Design, Synthesis and SAR of Pharmacophore for Microtubule-Stabilizing meeting, Anaheim, CA, March 21-25, MED	Novel Hybrid Constructs B g Agents" <i>Book of Abstracts</i> DI-038, 1999.	s, 217 <sup>th</sup> ACS National
	cin, et al., "Design and Synthesis of Taxoio ACS National Meeting, Boston, August 23	-	k of Abstracts, 216th

FORM PTO-1449	U.S. Department of Commerce	ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION D	ISCLOSURE STATEMENT	APPLICANT: Danishefsk	ty et al.
(Use several s	sheets if necessary)	FILING DATE:	GROUP:
		December 4, 2001	1626
Mi	icrotubules", J. Am. Chem. Soc. 119: 874	14-8745, 1997.	· · · · · · · · · · · · · · · · · · ·
	st, et al., "Proline-Catalyzed Direct Asyr 95-2396, 2000.	nmetric Aidoi Reactions J.	Am. Chem. Soc. 122:
Me	u, et al., "Total Synthesis of Epothilone aethoxybenzyl Ether of Epothilone C" Ch	em. Eur. J., 8(16): 3747-375	56, 2002.
Te	u, et al., "Epoxide Opening with Acetylic trahedron Lett. 39(29): 5261-5264, 1998	3.	
(19	u et al., "Chiral Synthesis of the C <sub>3</sub> -13 Se 997) thgoe, et al., "Allylic Phosphine Oxides		
Sy	nthesis of 3-Deoxyvitamin D <sub>2</sub> ", <i>Tetrahe</i> achajewski, et al., "Chemoenzymic Synt	dron Lett. <b>40</b> :3863-3866, 19	75.
(S <sub>I</sub>	pec. Iss.), 1469-1472, 1999.		
Sy Ch	nthesis of Epothilone B and the Synthes tem. Eur. J, 42(47): 8373-8377, 2001.	ion Approach for a Truly Stereocontrolled Total hesis of a Conformationally Restrained Analog".	
Ed	7,39(3): 581-583, 2000.	Novel Synthesis of Epothilone B" Angew. Chem. Int.	
	ay, et al., "Total Synthesis of (-) Epothilo		<u> </u>
Ep Me	Daid et al., "Validation of the Pharmacon othilone B, During a Phase I Clinical Streng et al. "Total Synthesis of Epothilone	udy" Clinical Cancer Resear	ch 8:2035-2043, 2002.
Me the	(1997).  Meng et al. "Studies toward a Synthesis of Epothilone A: Use of Hydropyran Templates for the Management of Acyclic Stereochemical Relationships" <i>J. Org. Chem.</i> 61:23 7998-8001 (1996).		
II	oasser et al., "Farnesyl transferase inhibioc. Natl. Acad. Sci. USA, 95:1369-1374		sensitivity to taxol"
Ep	Molnar, et al., "The Biosynthetic Gene Cluster for the Microtubule-Stabilizing Agents Epothilones A and B from Sorangium Cellulosum So ce90" <i>Chem. Biol.</i> , 7(2): 97-109, 200		<i>l.</i> , 7(2): 97-109, 2000.
Sta	ooberry, et al., "Laulimalide and Isolauli abilizing Agents", Cancer Res. <b>59</b> : 653-6	580, 1999.	e Microtubule-
	orrissey, et al., <i>J. Am. Chem. Soc.</i> 107: 4 ulzer, et al., "Total Syntheses of Epothilo		<b>65</b> (22): 7456-7467
20	00.		
, i	ulzer, et al., "A Novel Highly Stereosele 2R,13R) Acetonide" <i>Tetrahedron Lett</i> , 4	•	thilone B and of its

FORM PTO-1449	U.S. Department of	ATTY. DOCKET:	IN RE
	Commerce	2003080-0071	APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION I	DISCLOSURE STATEMENT	APPLICANT: Danishe	fsky et al.
(Use several sheets if necessary)		FILING DATE:	GROUP:
		December 4, 2001	1626
	Mulzer, et al., "Synthesis of the C(11)-C(26", Tetrahedron Letters", 38(44):7725-772	, -	cic Macrolide Epothilone
	Mulzer, et al "Easy Access to the Epothile Tetrahedron Letters, 39(47): 8633-8636, 1		Epothilone B",
	Julzer, "Progress in the Synthesis of Chiratertrolon B" J. Heterocycl. Chem., 36(6):		oducts: Epothilone B and
I	lagaoka, et al., "Further Synthetic Studies 981.	on Rifamycin S", Tetraho	edron, <b>37</b> : 3873-3888,
	Jahm, et al., "N-Methoxy-N-Methylamide 2: 3815-3818, 1981.	s as Effective Acylating A	Agents", Tetrahedron Lett.
	Takamura, S., "Total Synthesis of Antitum f Action with Taxol", <i>Kagaku (Kyoto)</i> ", (		
N	Newman, et al., "Antitumor Efficacy of 26-Fluoroepothilone B Against Human Prostate Cancer Xenografts" Cancer Chemother. Pharmacol., 48(4): 319-326, 2001.		
l l	Nicolaou, et al., "Synthesis and Biological Evaluation of 12, 13-cyclopropyl and 12,13-cyclobutyl Epothilones" ChemBioChem (Angew. Chem. Int. Ed. Engl.), 2(1): 69-75, 2001.		
	Nicolaou, et al., "Recent Developments in the Chemistry, Biology and Medicine of the Epothilones" Chem. Commun., 17:1523-1535, 2001.		nd Medicine of the
c	ficolaou, et al. "Chemical Synthesis and Eyclopropyl and 12,13-cyclobutyl Epothilom. Chem. Soc., 123(38): 9313-9323, 2001	nes and Related Pyridine	
N R	licolaou, et al., "Synthesis of 16-desmethy apid, Highly Selective and Convergent Commun., 6:519-520, 1999.	lepothilone B: Improved	
N ar	ficolaou, et al., "Total Synthesis of 16-Deand Related Side Chain Modified Epothilos 000.		
1	ficolaou, et al., "Chemical Synthesis and I Them. Biol. 7(8): 593-599, 2000.	Biological Properties of Py	ridine Epothilones"
	ficolaou, et al., "Chemistry, Biology and Nure Appl. Chem., 71(6): 989-997, 1999.	Medicine of Selected Tubi	ılin Polymerizing Agents"
	icolaou et al. "Synthesis and Biological Pelated Epothilones" Chem. Biol, 5(7): 365	1	propyl-Epothilone A and
N	icolaou, et al., "Total Synthesis of Epothi ia a Stille Coupling Based Strategy" Bioo	lone E and Related Side-C	_
N	icolaou, et al., Chemie und Biologie der I	Epothilone, Agnew. Chem	., <b>110</b> : 2120-2153, 1998.
	icolaou, et al., "Chemistry and Biology o	f Taxol", Angew. Chem. I	nt. Ed. Engl. 33: 15-44,
N	icolaou, K.C. et al. "Total Synthesis of E	pothilone E and Analogue	s with Modified Side

FORM PTO-1449	U.S. Department of	ATTY. DOCKET:	IN RE	
(DELL 0.02)	Commerce	2003080-0071	APPLICATION NO.:10/004,571	
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	11010/004,3/1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefs	sky et al.	
(Use several sheets if necessary)		FILING DATE:	GROUP:	
		December 4, 2001	1626	
	ains through the Stille Coupling Reaction			
Nat 104	colaou, et al., "Ring-Closing Metathesis tural Products" <i>Top. Organomet. Chem.</i> 1, 1998.	1 (Alkene Metathesis in O	rganic Synthesis)1: 73-	
Ma	colaou, K.C. et al., "Total Synthesis of 2 crolactonization Based Strategy" <i>Tetral</i>	nedron <b>54</b> : 7127-7166 (199	8).	
100	colaou, et al., "Synthesis of Epothilones: ), 1997.			
Les 104	ordarson, et al., "Discovery of Potent Cessons from Structure – Activity Studies (10, 2004.	of (+)- Migrastatin", J. Am.	Chem. Soc. 126:1038-	
	thilone series: novel epothilone analogs	erto unexplored macrocyclization strategies in the nalogs by total synthesis, <i>Chem. Commun.</i> , 2759-2761,		
Che	•	ogenation of β-Keto Carboxylic Esters. A Practical, Purely sters in High Enantiomeric Purity" <i>J. Am. Chem. Soc.</i> 109:		
Age	ma, et al., "New-Generation Taxoids an ents" <i>Book of Abstracts, 219<sup>th</sup> ACS Nati GN-245</i> , 2000.	d Hybrids of Microtubule- onal Meeting, San Francis	Stabilizing Anticancer co, CA, March 26-30,	
	ma, et al., "A Common Pharamcophore crotubules <i>Proc. Natl. Acad. Sci. U.S.A.</i>		lucts that Stabilize	
	ma, et al., "Enantiopure Fluorine-Contarsatile Probes for Biomedical Problems"			
Ena	nicker <i>et al.</i> , "An unusual Reversal of Stantioselective Synthesis of the C1-C6 Sec. 19-7868, 2000.			
App 36:	erson et al., "Stereocontrolled Aldol Ad plication to the Synthesis of a $C_{13}$ - $C_{25}$ S 175-178, 1995.	egment of Bafilomycin A <sub>1</sub> '	'Tetrahedron Lett.	
End	rache <i>et al.</i> , "The Role of the Microtubu dothelial Cell Permeability" <i>Am. J. Resp</i>	ir. Cell Mol. Biol. 28:574-	581, 2003.	
Che	tet et al., "Isolation and Structure of the em. Soc. Chem. Commun. 1111-1112, 19	994.		
i i	della et al., "Characterisation, Genome	_		
	xobacterium Sorangium Cellulosum So	<del>. 1 - 1 </del>		
Site	or et al., "The Microtubule Stabilizing A c, Kills Cells Resistant to Paclitaxel and iety for Activity" Biochemistry 41:9109	Epothilones, and May Not		

FORM PTO-1449	U.S. Department of Commerce	ATTY. DOCKET:	IN RE APPLICATION	
(DEV 0.02)		2003080-0071	NO.:10/004,571	
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	14010/004,571	
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefsky	et al.	
(Use several sheets if necessary)		FILING DATE:	GROUP:	
		December 4, 2001	1626	
	Quitschalle et al., "Improved Synthesis of			
	Sharpless Asymmetric Dihydroxylation" To Regentin et al., "Development of a Cost Ef			
	Xanthus" Abstr. Pap-Am. Chem. Soc. 221 <sup>st</sup>		in myxococcus	
	Regentin et al., "Nutrient Regulation of Ep	othilone Biosynthesis in Hete	erologous and Native	
]	Production Strains" Appl. Microbiol. Biotec	chnol. 61:451-455, 2003.		
	Regueiro-Ren <i>et al.</i> , "Synthesis and Biolog Lett. 3(17): 2693-2696, 2001.	ncal Activity of Novel Epoth	ilone Aziridines" Org.	
	Regueiro-Ren <i>et al.</i> , SAR and pH Stability 4(22): 3815-3818, 2002.	of Cyano-Substituted Epothi	lones, Organic Letters,	
	Reiff et al., "Progress Toward Total Synthe 215 <sup>th</sup> ACS National Meeting, Dallas, Marc	h 29-April 2, ORGN-086	_	
] ]	Rivkin, et al., "Complex Target-Oriented To Discovery of a Highly Promising Family of Soc, 125:2899-2901, 2003.	nplex Target-Oriented Total Synthesis in the Drug Discovery Process: The hly Promising Family of Second Generation Epothilones" J. Am. Chem.		
]   t	Ring-Closing Metathesis-Based Strategy: Che Epothilone Series" J. Org. Chem., 67:7	and [18] Dehydrodesoxyepothilones B via a Consise y: Correlation of Ring Size with Biological Activity in 7:7737-7740, 2002.		
(		Trifluoromethyl Substituent in the Epothilone Setting: ng Olefin Metathesis and Earliest Biological Findings" 2.		
	Roush et al., "Acyclic Diastereoslective Sy			
	Crotylboronates. Double Asymmetric Read Synthesis of the C(19)-C(29) Segment of R 1990.			
]	Santi <i>et al.</i> , "An Approach for Obtaining Polyketide Synthase Genes: A Search for tall 102, 2000.	the Epothilone Gene Cluster"	Gene, <b>247</b> (1-2): 97-	
ı	Sawada et al., "Enantioselective Total Synt Asymmetric Catalysis" Angew. Chem. Int.	-	Multifunctional	
1		Synthesis of Epothilones A and B Using S' J. Am. Chem. Soc. 122(43):10521-10532, 2000.		
	Schiff et al., "Promotion of Microtubule And 1979.	otubule Assembly in vitro by Taxol" Nature, 277:665-667,		
] 4	Scholl <i>et al.</i> , "Increased Ring Closing Meta Metathesis Catalysts Coordinated with Imid 40:2247-2250, 1999	dazolin-2-Ylidene Ligands",	Tetrahedron Lett.	
	Schrock, "Olefin Metathesis by Well-Defin Organomet. Chem. 1:1-36, 1998.	ned Complexes of Molybdenu	ım and Tungsten" <i>Top</i> .	

FORM PTO-144	<b>▲</b>	ATTY. DOCKET:	IN RE
	Commerce	2003080-0071	APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION	N DISCLOSURE STATEMENT	APPLICANT: Danishefs	ky et al.
(Use seve	ral sheets if necessary)	FILING DATE:	GROUP:
		December 4, 2001	1626
	Scudiero <i>et al.</i> , "Evaluation of a Soluble To Drug Sensitivity in Culture Using Human a 4833, 1988.	and Other Tumor Cell Line	s", Cancer Res. <b>48</b> :4827-
	Sefkow et al., "Derivatization of the C12-C Bioorg. Med. Chem. 8:3031-3036, 1998.		
	Sefkow <i>et al.</i> , "Oxidative and Reductive T <i>Chem.</i> <b>8</b> (21):3025-3030, 1998.	<u> </u>	
	Sefkow <i>et al.</i> , "Substitutions at the Thiazol <b>48</b> (12):2485-2488, 1998.		
	Schinzer et al., "Total Synthesis of (-)-epo		<u> </u>
	Schinzer et al., "Total Synthesis of (-)-epo		· ·
	Schneider et al., "Utilization of Alternate S Epothilone Synthetase Assembly Line" J. A.	4m. Chem. Soc. 124:11272-	-11273, 2002.
		"Increased Ring Closing Metathesis Activity of Ruthenium-Based Olefin atalysts Coordinated with Imidazolin-2-Ylidene Ligands" Tetrahedron Lett.	
	t e e e e e e e e e e e e e e e e e e e	uble Tetrazolium/Formazan Assay for Cell Growth and Juman and Other Tumor Cell Lines" Cancer Research	
	Shibasaki <i>et al.</i> , "Multifunctional Asymme 2001.	tric Catalysis" Chem. Phar	m. Bull., <b>49</b> (5):511-524,
	Shioji et al., "Synthesis of C1-C6 Fragmer Resolution" Synth. Commun., 31(23):3569		se-Catalyzed Optical
·	Sinha, et al., "The Antibody Catalysis Rou <i>Acad. Sci.</i> <b>95</b> (25):14603-14608, 1998.	te to the Total Synthesis of	Epothilones" Proc. Natl.
	Sinha, et al., "Catalytic Antibody Route to Synthesis of Epothilones A-F" Chem. Eur.	<i>J.</i> 7(8):1691-1702, 2001.	
	Sinha et al., "Total Synthesis of Epothilon Catalysis" Book of Abstracts, 217th ACS No ORGN-054	ational Meeting, Anaheim,	CA, March 21-25,
	Sinha et al., "Synthesis of Epothilone Ana Thiazole Aldol Synthons on a Multigram S of Epothilones" Chem. Bio. Chem., 2(9):6	Scale. Biological Conseque 56-665, 2001.	nces of C-13 Alkylation
	Sinha et al., "Sets of Aldolase Antibodies Epothilone E by Large Scale Antibody-Ca 1(10):1623-1626, 1999.	talyzed Resolution of Thiaz	cole Aldol" Org. Lett.,
	Sinha et al., "Regioselective Synthesis of I Syntheses via Antibody Catalysis" Tetrahe	edron Letters, 41(43):8243-	8246, 2000.
	Skehan et al., "New Colorimetric Cytotoxi	city Assay for Anticancer-l	Drug Screening" Journal

FORM PTO-1449	U.S. Department of Commerce	ATTY. DOCKET: 2003080-0071	IN RE APPLICATION
(REV. 8-83)	Patent and Trademark Office		NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefsk	xy et al.
(Use several	sheets if necessary)	FILING DATE:	GROUP:
		December 4, 2001	1626
	f the National Cancer Institute, 82:1107-1		
1	mart, "Fluorine Substituent Effects (on bi 1, 2001.	•	
P	tachel et al., "The Epothilones, Eleuthero Pharm. Des. 7(13):1277-1290, 2001.	<del></del>	
. D	tachel et al., "On the Interactivity of Compression Drug Discovery Process: Total Synthesis a Epothilones" J. Org. Chem. 66:4369-4378,	and Comparative in Vivo Ev 2001.	aluations of the 15-Aza
	u et al., "Structure-Activity Relationships Comparison with Paclitaxel" Angew. Chem.		
a	u et al., "Total Synthesis of (-) Epothilone and Insights into Structure-Activity Relationals. 36:757-759, 1997.		
	un et al. "Stereoselective Total Synthesis avolving C9-C10 Bond Formation" Angev	sis of Epthilones by the Metathesis Approach gew. Chem. Int. Ed. 8:1381-1383, 2002.	
	ang et al., "Cloning and Expression of the 000.	f the Epothilone Gene Cluster" Science, 287:640-642,	
В	ang et al., "Generation of Novel Epothilo intransformation" The Journal of Antibio	tics, <b>56</b> :16-23, 2003.	
E	animori et al., "Simple Synthesis of Both pothilones" Biosci. Biotechnol. Biochem,	<b>62</b> (12):2428-2430, 1998.	
S	animori et al., "Easy Access to Both Ena ynth. Commun. 29(24): 4353-4360, 1999.		<u>-</u>
	aylor et al., "Total Synthesis of Epothilon	<del>-</del>	
	aylor et al., "The Identification of the Bio of Abstracts, 217 <sup>th</sup> ACS National Meeting, 1	Anaheim, CA, March 21-25,	ORGN-041
	aylor et al., "The Conformational Propert 5(17):5449, 2000.	ies of Epothilone"-Erratum.	J. Org. Chem.,
	aylor et al., "Conformational Properties o	f Epothilone" J. Org. Chem.	64(19):7224-7228,
Ir 1:	aylor <i>et al.</i> , "Catalytic Diastereoselective nterdependent Reaction Variables by Arra <b>21</b> :12202-12203, 1999.	yed Catalyst Evaluation" J.	Am. Chem. Soc.
C	aylor, "A Formal Total Synthesis of Epotal and C7-C12 Fragments" <i>J. Org. Chem.</i>	<b>63</b> (25):9580-9583, 1998.	
H	oh <i>et al.</i> , "Studies on a Convergent Route lydroxy-23-Oxavitamin D <sub>3</sub> " <i>J. Org. Chem</i>	. <b>48</b> :1414-1417, 1983.	***
	rnka et al., "The Development of $L_2X_2Ru$ organometallic Success Story" Acc. Chem.		talysts: An

FORM PTO-144		ATTY. DOCKET:	IN RE
	Commerce	2003080-0071	APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON4)	NO.:10/004,571
INFORMATION	INFORMATION DISCLOSURE STATEMENT APPLICANT: Danishefsky et al.		et al.
(Use sever	al sheets if necessary)	FILING DATE:	GROUP:
		December 4, 2001	1626
	Trnka et al., "The Development of L2X2Ri		talysts: An
	Organometallic Success Story" Acc. Chem. Tsuji et al., "Alterations in Cellular Adhesi		al Cells
	Overexpressing Prostaglandin Endoperoxic		
	Valluri et al., "Total Synthesis of Epothilor		
	Victory et al., "Development of an Epothilo National Meeting, Dallas, March 29-April		Abstracts, 215 <sup>th</sup> ACS
	Von Angerer, "Tubulin as a Target for Anti 3(5):575-584, 2000.		
	Wessjohann et al., "Synthesis of Natural-Prochem. Biol. 4:303-309, 2000.	roduct-Based Compound Lib	raries" Curr. Opin.
	Wessjohann et al., "Synthetic Access to Ep Anticancer Activity" Org. Synth. Highlight		
	Weinheim Germany, 251-267, 2000.		
	White et al., "Total Synthesis of Epothilone Dehydroepothilone D" J. Am. Chem. Soc.,	<del>-</del>	10 trans-9,10-
	White et al., Total Synthesis of Epothilone	B, Epothilone D, and cis-and	
	Dehydroepothilone D, J. Am. Chem. Soc., 1	25:3190, 2003, Additions an	d Corrections.
	White, et al., "Synthetic Approach Towards Abstracts, 216th ACS National Meeting, Bo.	ston, August 23-27, ORGN-0-	41
	White, et al., "A Highly Stereoselective Sys 685, 1999.	nthesis of Epothilone B" J. O	rg. Chem., <b>64</b> (3):684-
	White, et al., "Improved Synthesis of Epoth Assembly of Subunits" Org. Lett., 1(9):143		on of an Alkyne for
	Winkler, et al., "A Model for the Taxol (Pa Chem. Letter, 6: 2963-2966, 1996.		ophore", Bioorg., Med.
	Winkler, et al., "Design and Synthesis of C Synthesis of Eleven-Membered Rings by C 1999.	lefin Metathesis" Tetrahedro	on, <b>55</b> (27): 8199-8214,
	Wittmann, et al., Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis, <i>Cancer Research</i> , <b>63</b> : 93-99, 2003.		
	Wolff, A., "Epothilone A Induces Apoptosi Mechanisms of Drug Resistance", <i>Int. J. Oi</i>	ncol., 11(1):123-126, 1997.	
	Woltering, et al., Development of a Novel In Vitro Human Tissue-Based Angiogenesis As to Evaluate the Effect of Antiangiogenic Drugs, <i>Annals of Surgery</i> , <b>237</b> : 790-800, 2003.		
	Wu et al. "Subtle Variations in the Long-Ramatched and Mismatched Aldol Reactions"		

FORM PTO-14 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	2003	Y. DOCKET: 080-0071 744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATIO	N DISCLOSURE STATEMENT	APPI	LICANT: Danishefsky	et al.
(Use seve	ral sheets if necessary)	FILI	NG DATE:	GROUP:
		Dece	mber 4, 2001	1626
	Yang, et al., "Total Synthesis of Epothilone Chem. Int. Ed., 36: 166-168, 1997.	A: Th	e Olefin Metathesis Ap	pproach: Angew.
	· · · · · · · · · · · · · · · · · · ·	et al., "Synthesis ad Conformational Analysis of (E)-9, 10-Dehydroepothilone B: A Link between the Chemistry and Biology of Epothilones", Angew. Chem. Int. Ed. 521, 2003.		
		s of Noscapine Are Potent Microtubule-Interfering Agents Il Proliferation, <i>Molecular Pharmacology</i> , <b>63</b> :799-807,		
	Zhu, et al., "Methodology Based on Chiral Natural Products-Total Synthesis of Epothi	lone A'	"Eur. J. Org. Chem., 9	): 1701-1714, 2001.
	ACS National Meeting, Boston, August 23	dies Toward the Total Synthesis of Epothilone A" Book of Abstracts, 216 <sup>th</sup> deeting, Boston, August 23-27, ORGN-660		
	l •	Thiazole-Containing Vinyl Carbinols. Synthesis of the Tetrahedron Lett., 41(12):1863-1866, 2000.		
EXAMINER			DATE CONSIDERI	ED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

3805070

applicant.

3753568v1